Codexis (CDXS) Upgraded to Buy at BidaskClub
Codexis (NASDAQ:CDXS) was upgraded by BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.
A number of other analysts have also recently commented on the company. HC Wainwright restated a “buy” rating and issued a $8.50 price objective on shares of Codexis in a research report on Tuesday, November 21st. Jefferies Group boosted their price objective on Codexis from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Friday, October 13th. Zacks Investment Research upgraded Codexis from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Finally, ValuEngine upgraded Codexis from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $7.50.
Codexis (CDXS) traded up $0.15 during trading on Friday, hitting $7.70. The stock had a trading volume of 300,009 shares, compared to its average volume of 233,598. Codexis has a 1-year low of $3.60 and a 1-year high of $7.95.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/16/codexis-cdxs-upgraded-to-buy-at-bidaskclub.html.
Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.
Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.